Clinicopathological characteristics of pheochromocytoma/paraganglioma and screening of prognostic markers
- PMID: 37272486
- DOI: 10.1002/jso.27358
Clinicopathological characteristics of pheochromocytoma/paraganglioma and screening of prognostic markers
Abstract
Background: Malignant pheochromocytoma/paraganglioma (PCPG) is lethal and difficult to diagnose before metastasis. This study is aiming to characterize the PCPG and explore novel prognostic markers.
Methods: Clinical data of patients with pathologically confirmed invasive and noninvasive PCPG were collected and analyzed. Then, the differentially expressed genes (DEGs) and HUB genes were identified by R package "limma" in GSE67066-GPL570. Afterward, the prognostic markers were screened out using R packages of "survival" and "survminer" based on the TCGA data.
Results: The 34 invasive PCPGs were characterized by irregular contour and unclear boundary on CT and capsule/extracapsule tissue invasion on pathology compared with the 42 noninvasive PCPGs. Then, 29 upregulated and 30 downregulated DEGs were identified in malignant PCPG compared with benign, which were mainly enriched in the terms of calcium ion binding, neuron cell-cell adhesion, axon, regulation of hormone levels, and regulation of secretion by cell. Of which, nine DEGs were furtherly selected as the HUB genes. Finally, CNTN4 and SH3GL2 were found to be highly expressed in malignant PCPGs and negatively correlated with progression-free interval.
Conclusions: Malignant PCPGs tend to be aggressive in imaging and pathology. The high expression of CNTN4 and SH3GL2 in PCPGs may indicate a poor prognosis.
Keywords: bioinformatic analysis; clinicopathology; paraganglioma; pheochromocytoma; prognostic marker.
© 2023 Wiley Periodicals LLC.
Similar articles
-
Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.Int J Cancer. 2020 Apr 15;146(8):2326-2335. doi: 10.1002/ijc.32654. Epub 2019 Oct 11. Int J Cancer. 2020. PMID: 31469413 Free PMC article.
-
Identification of vital prognostic genes related to tumor microenvironment in pheochromocytoma and paraganglioma based on weighted gene co-expression network analysis.Aging (Albany NY). 2021 Mar 26;13(7):9976-9990. doi: 10.18632/aging.202754. Epub 2021 Mar 26. Aging (Albany NY). 2021. PMID: 33795528 Free PMC article.
-
Bioinformatic analysis of differentially expressed genes as prognostic markers in pheochromocytoma and paraganglioma tumors.Genes Genet Syst. 2021 Jul 14;96(2):55-69. doi: 10.1266/ggs.20-00057. Epub 2021 May 26. Genes Genet Syst. 2021. PMID: 34039789
-
15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma.Endocr Relat Cancer. 2015 Aug;22(4):T123-33. doi: 10.1530/ERC-15-0261. Epub 2015 Jul 1. Endocr Relat Cancer. 2015. PMID: 26136457 Review.
-
Pathology and genetics of phaeochromocytoma and paraganglioma.Histopathology. 2018 Jan;72(1):97-105. doi: 10.1111/his.13402. Histopathology. 2018. PMID: 29239044 Review.
Cited by
-
Identification of prognostic genes related to T cell proliferation in papillary thyroid cancer based on single-cell RNA sequencing and bulk RNA sequencing data.Clin Exp Med. 2025 Aug 2;25(1):273. doi: 10.1007/s10238-025-01826-5. Clin Exp Med. 2025. PMID: 40753315 Free PMC article.
-
Subclinical paraganglioma of the retroperitoneum: A case report.World J Clin Cases. 2024 May 26;12(15):2672-2677. doi: 10.12998/wjcc.v12.i15.2672. World J Clin Cases. 2024. PMID: 38817224 Free PMC article.
-
Factors linked to lung cancer in MIMIC-IV database.J Thorac Dis. 2025 May 30;17(5):2765-2777. doi: 10.21037/jtd-2024-1998. Epub 2025 May 26. J Thorac Dis. 2025. PMID: 40529779 Free PMC article.
-
Integrated single-cell and bulk RNA dequencing to identify and validate prognostic genes related to T Cell senescence in acute myeloid leukemia.Front Bioinform. 2025 Jun 25;5:1606284. doi: 10.3389/fbinf.2025.1606284. eCollection 2025. Front Bioinform. 2025. PMID: 40635996 Free PMC article.
-
Exploration and validation of the prognostic value of mitophagy and mitochondrial dynamics-related genes in cervical cancer.Sci Rep. 2025 Jul 10;15(1):24950. doi: 10.1038/s41598-025-09310-6. Sci Rep. 2025. PMID: 40640353 Free PMC article.
References
REFERENCES
-
- Neumann HPH, Young Jr. WF, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019;381(6):552-565.
-
- Dobrowolski P, Januszewicz A, Klisiewicz A, et al. Left ventricular structural and functional alterations in patients with pheochromocytoma/paraganglioma before and after surgery. Cardiovasc Imag. 2020;13(12):2498-2509.
-
- Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476-1490.
-
- Corssmit EPM, Snel M, Kapiteijn E. Malignant pheochromocytoma and paraganglioma: management options. Curr Opin Oncol. 2020;32(1):20-26.
-
- Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr-Relat Cancer. 2014;21(3):405-414.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous